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ABSTRACT 1 
Glycodelin contains four isoforms with diverse biological functions.  Glycodelin-A is 2 
potential diagnostic marker for cancer patients  and  receptive marker of secretory 3 
endometrium.  Yet, direct evidence of glycodelin on regulating endometrial epithelial cells 4 
migration, invasion and attachment of trophoblastic spheroids (blastocyst surrogate) is 5 
lacking. In this study, the human glycodelin gene was stably transfected into the human 6 
endometrial (HEC1-B) cells.  Forced-expression of glycodelin in HEC1-B cells did not 7 
affect cell proliferation, cell viability and cell cycle progression, but significantly reduced 8 
migration and invasion of the stably transfected cells. The migration rate returned to 9 
normal levels when the glycodelin stably expressing HEC1-B cells were treated with 10 
glycodelin RNAi. Furthermore, forced-expression of glycodelin in HEC1-B cells 11 
significantly increased the attachment of trophoblastic spheroids onto the endometrial 12 
epithelial cells.  In sum, glycodelin suppressed endometrial cell migration/invasion but 13 
enhanced spheroids attachment. 14 
 15 
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INTRODUCTION 1 
The lipocalin subfamily member glycodelin has several isoforms found in the reproductive 2 
system, namely glycodelin-A (GdA), glycodelin-F (GdF), glycodelin-S (GdS), and 3 
glycodelin-C (GdC) (Seppala et al., 2007). The exact biological function of glycodelin 4 
remains unknown, but it is believed to play important roles on endometrial receptivity, 5 
maternal-fetal immunity, and gynecological cancer progression. For example, GdA inhibits 6 
sperm-oocyte interaction by binding onto the sperm head; GdS in seminal plasma 7 
maintains sperm in an uncapacitated state; GdF in follicular fluid and the Fallopian tube 8 
inhibits sperm-oocyte binding and the premature progesterone-induced acrosome reaction; 9 
and GdC in cumulus matrix displaces sperm-bound inhibitory glycodelin isoforms and 10 
enhances sperm-oocyte binding (Seppala et al., 2007; Yeung et al., 2009).  11 
Glycodelin-A, a progesterone-regulated glycoprotein, is highly expressed during the 12 
secretory phase in the human endometrium (Seppala et al., 2002). The level of GdA 13 
gradually increases in the endometrial glands 4 to 5 days after ovulation and reaches its 14 
peak on day 10, coinciding with the window of implantation (WOI) (Seppala et al., 2002; 15 
Carson et al., 2002). Embryo implantation involves apposition and adhesion of embryo to 16 
the endometrial epithelium, penetration of the endometrial epithelium, and invasion of the 17 
extravillous trophoblast cells through the decidualized endometrial stromal cells (Bentin-18 
Ley et al., 1999). Among various steps in implantation, attachment of embryo onto 19 
endometrial epithelial cells is essential for successful implantation and pregnancy. For 20 
example, pinopodes are formed at the apical region of the endometrium that facilitate 21 
adhesion of blastocyst to the endometrial surface (Bentin-Ley et al., 1999). Moreover, 22 
embryo implantation is regulated by various endometrial adhesive (e.g. integrins) and anti-23 
adhesive (e.g. MUC1) factors (Chervenak and Illsley, 2000). Expressions of these adhesive 24 
and anti-adhesive factors are associated with an increase in glycodelin expression during 25 
WOI ( Hohn et al., 2000; Seppala et al., 2002;). Furthermore, several microarray studies 26 
  4
have compared gene expression patterns of the endometrium during the menstrual cycle 1 
(Carson et al., 2002; Talbi et al., 2006). A large number of genes showed cyclical variation 2 
in expression, but only a few genes including osteopontin, apolipoprotein D, 3 
dickkopf/DKK1 and olfactomedin were found to be common in all these studies 4 
(Horcajadas et al., 2004). Abnormal levels of glycodelin are associated with unexplained 5 
infertility and early pregnancy loss (Seppala et al., 2009).  6 
Glycodelin is also involved in the progression of gynecological cancers. An aberrant 7 
expression of glycodelin is associated with endometrial, ovarian and breast cancers 8 
(Seppala et al., 2009). Forced-expression of glycodelin in breast cancer cell lines and 9 
cancer cell xenografts reverses the malignant phenotype of the cells (Kamarainen et al., 10 
1997; Hautala et al.,2008). How glycodelin modulates these changes has yet to be 11 
determined. In the present study, we stably transfected glycodelin gene in human 12 
endometrial (HEC1-B) cell line and studied the effects of glycodelin force-expression on 13 
cell migration, cell invasion, and trophoblastic spheroids attachment onto the endometrial 14 
cells. 15 
  16 
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MATERIALS AND METHODS 1 
Cell lines and forced-expression of glycodelin in HEC1-B cells 2 
Human endometrial adenocarcinoma cells (HEC1-B,  Cat no.: HTB-113) were obtained 3 
from ATCC (Manassas, VA, USA) and cultured in Minimal Essential Medium (MEM) 4 
(Sigma, St Louis, MO, USA) supplemented with 10 % fetal bovine serum (Invitrogen, 5 
Carlsbad, CA, USA), 100 units/ml penicillin (Invitrogen), and 100 µg/ml streptomycin 6 
(Invitrogen) at 37 °C under 5% CO2 in a humidified incubator. Total RNA from human 7 
endometrial tissue was purified using the Absolutely RNA RT-PCR miniprep kit 8 
(Stratagene, La Jolla, CA, USA). Total RNA was reverse transcribed using the First strand 9 
cDNA synthesis kit (Amersham, Pittsburgh, PA, USA). The human glycodelin cDNA was 10 
amplified by PCR using a glycodelin forward primer (5’-11 
GTCAAGCTTGATGGACATCCCCAGACCA-3’, HindIII site underlined) and a 12 
glycodelin reverse primer (5’-GAGGAATTCTTCGAAACGGCACGGCTCTTCCAT-3’, 13 
EcoRI site underlined). The glycodelin coding region was cloned into the pHM6 14 
mammalian expression vector (Roche Diagnostics Co., Switzerland). This vector was then 15 
transfected into HEC1-B cells using lipofectamine 2000 (Invitrogen). The selection of the 16 
stable clones was carried out using 50 µg/ml G418 for one month. The stable clones were 17 
maintained in MEM medium containing supplements and 50 µg/ml G418.  All the 18 
experiments were performed in passage 5 to 10 of the stable selected HEC1-B clones. 19 
 20 
Quantitative PCR 21 
Total RNA isolated from cultured cells was reverse transcribed with TaqMan reverse 22 
transcription reagent kit (Applied Biosystems, Foster City, CA, USA) and multi-script 23 
reverse transcriptase. The resulting cDNAs were analyzed using qPCR on a glycodelin 24 
TaqMan probe (Hs00171462_m1, Applied Biosystems). Quantitative PCR was performed 25 
using a 7500 Real-Time PCR System (Applied Biosystems). Multiplex PCR was 26 
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performed on 20 μl volumes containing 5 μl of sample cDNA, 10 μl 2X TaqMan Universal 1 
PCR Master Mix, 1 μl 20X Gene Expression Assay for targets and 1 μl eukaryotic 18S 2 
rRNA as the internal control. The relative levels of gene expression were detected using the 3 
threshold cycle (CT) method (also known as the 2-ΔΔCT method) using endogenous 18S as 4 
the internal control.  All the experiments were performed in triplicates and repeated at least 5 
3 times. 6 
 7 
Western blotting 8 
Total proteins from HEC1-B were dissolved in RIPA solution (1X PBS, 1% Nonidet P-40, 9 
0.5% sodium deoxycholate, 0.1 % SDS) containing protease inhibitors. The samples were 10 
separated on 12% SDS-PAGE and the proteins were transferred to a PVDF membrane. 11 
After thorough washing, the membrane was probed with glycodelin antibody (rabbit 12 
antibody raised against glycodelin peptide, amino acids 69-83) at 1:1000 dilution, α-13 
tubulin (1:5000, Santa Cruz, Santa Cruz, CA, USA) and β-actin antibody (1:5000, Sigma). 14 
Positive signal was detected by chemiluminescence using goat anti-rabbit or goat anti-15 
mouse IgG conjugated-HRP secondary antibodies. 16 
 17 
Flow cytometry 18 
Transfected HEC1-B cells were collected and fixed in 70 % ethanol. The cells were 19 
washed in phosphate buffered saline twice and stained with 2.5 µg/ml propidium iodide. 20 
DNA content was measured by flow cytometry on a BD FACSCantoII Analyzer (BD 21 
Biosciences, San Jose, CA, USA) equipped with a 488 nm argon laser. Fluorescence 22 
signals were measured using a 585 nm band pass filter. The results were analyzed using 23 
WinMDI 2.9 (The Scripps Research Institute Cytometry Software, San Diego, CA, USA) 24 
and Cylchred (Cytonet UK, Cardiff, UK). 25 
 26 
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Cell Migration Assay 1 
The migration rate of glycodelin overexpressing HEC1-B cells was determined in a wound 2 
healing assay. Briefly, 2 x 105 HEC1-B cells in 2 ml MEM medium on 6-well plates were 3 
grown overnight at 37 °C. The cells were treated with 20 µg/ml mitomycin C (Sigma) for 3 4 
h. The culture medium was changed and a wound was created on each well using the tip of 5 
a pipette. The migration rate was expressed as a percentage of the width of the wound at 48 6 
h divided by the width of the wound at 0 h. 7 
 8 
Cell Invasion Assay 9 
The cell invasion of the transfected HEC1-B cells was studied using a BD Biocoat™ 10 
Matrigel™ Invasion Chamber (BD Biosciences). The invasion chambers used a 9 µm pore 11 
size polyethylene terephthalate membrane, which was chosen for this study because it 12 
could effectively block non-invasive cells from migrating through the membrane while 13 
allowing invasive cells to pass through. The HEC1-B cells (5 x 104 cells/ml in 0.5 ml 14 
serum-free MEM medium) were seeded on the invasion chamber and incubated at 37 °C 15 
for 24 h. The empty vector clone was used as the control. Non-invading cells were 16 
removed from the interior chamber by scrubbing with a cotton swab. The invading cells on 17 
the bottom of the membrane were stained with crystal violet stain for 25  min.  18 
 19 
RNAi transfection 20 
RNAi targeted against glycodelin (Human LOC649984, Thermo Fisher Scientific, 21 
Lafayette, CO, USA) was diluted to 10 nmol and transfected into glycodelin 22 
overexpressing HEC1-B cells using lipofectamine 2000 (Invitrogen).  23 
 24 
Spheroid Attachment Assay 25 
Spheroid Attachment Assay was performed as previously described (Kodithuwakku et al., 26 
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2011). Human trophoblastic JAr (blastocyst surrogate) and HEC1-B cells were used as the 1 
co-culture model. Spheroids (60-200 μm) were prepared from trypsinized JAr cells in an 2 
incubator at 37 oC and rotated at 100 rpm for 24 h. Spheroids were then transferred onto a 3 
confluent monolayer of transfected HEC1-B cells on a 12-well culture plate (in MEM with 4 
10 % FBS and 1 % L-glutamine). After incubation at 37 oC for 24 h, unattached spheroids 5 
were removed by shaking the culture plates at 140 rpm for 10 min. The attached spheroids 6 
that remained on the HEC1-B monolayer were then counted. The attachment rate was 7 
expressed as a percentage of the number of attached spheroids divided by the total number 8 
of spheroids added onto the HEC1-B monolayer. 9 
 10 
Statistical Analysis 11 
All the data were analyzed by statistical softwares (SigmaPlot 11.0 and SigmaStat 2.03; 12 
Jandel Scientific, San Rafael, CA, USA) and presented as Mean ± S.E.M.  The non-13 
parametric analysis of variance on rank test for multiple comparisons followed by the 14 
Mann-Whitney U test was used when the data were not normally distributed.  A probability 15 
value <0.05 was considered to be statistically significant.  16 
  17 
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RESULTS 1 
Forced-expression of glycodelin on cell growth 2 
The cDNA coding region of glycodelin was cloned into the pHM6 mammalian expression 3 
vector and transfected into HEC1-B cells. Gentamycin was used to select glycodelin 4 
forced-expressing clones (4-1 and 4-2), and the empty vector transfected control clone (1-5 
5). Western blotting results confirmed the expression of glycodelin protein in clones 4-1 6 
and 4-2, but not in clone 1-5 (Fig. 1A). Quantitative PCR results confirmed that the 7 
expression levels of glycodelin transcript in clones 4-1 and 4-2 were 105-fold higher than 8 
in clone 1-5 (Fig. 1A). Forced-expression of glycodelin had no effect on cell proliferation 9 
and cell viability in all the selected clones (data not shown). 10 
Flow cytometry was used to monitor the DNA content of stably transfected cells at 11 
different phases of the cell cycle. We analyzed the 2N (G0/G1 phase) and 4N (G2/M 12 
phase) DNA content. No changes were observed in the percentages of cells in G0/G1, S 13 
and G2/M phases in all the selected clones (Fig. 1B). This result was confirmed by qPCR 14 
of the cell cycle checkpoint transcripts including p16, p21 and p27 (data not shown). 15 
 16 
Forced-expression of glycodelin on cell migration and invasion 17 
Cells in the wound healing assay were treated with mitomycin C to suppress cell 18 
proliferation. Therefore, the change in area covered by cells was only caused by cell 19 
migration, but not division and proliferation. Forced-expression of glycodelin in HEC1-B 20 
cells in clones 4-1 and 4-2 suppressed the migration of the transfected HEC1-B cells when 21 
compared with the control clone 1-5 (Fig. 2A). The migration rates in clones 4-1 and 4-2 22 
were significantly lower (23% and 35%, respectively; p<0.05) than in control clone 1-5 23 
(51%). The effect of glycodelin on cell invasion was studied using a cell invasion chamber 24 
assay. The cell invasion of clones 4-1 and 4-2 was significantly decreased (30% each; 25 
p<0.05) compared with the control clone 1-5 (Fig. 2B). 26 
  10
 1 
Suppression of glycodelin in stably transfected cells increases cell migration 2 
RNAi knockdown of the glycodelin expression in the stably transfected clones was 3 
performed to confirm the effect of glycodelin on cell migration. The expression of 4 
glycodelin protein in clone 4-1 was found to be down-regulated by glycodelin RNAi 5 
compared with the control clone 1-5 (>50% reduction) (Fig. 2C). Transfection of 6 
glycodelin RNAi did not affect migration in the control clone 1-4, but significantly 7 
increased the migration rate (43%) in clone 4-1 (Fig. 2C). No changes in migration rate 8 
were observed when the cells were treated with non-target RNAi. 9 
 10 
Effect of glycodelin forced-expression on spheroid attachment 11 
Forced-expression of glycodelin in HEC1-B cells increased the rate of attachment of 12 
trophoblastic spheroids onto the endometrial epithelial cells (Fig. 3A). The rate of 13 
attachment of spheroids on glycodelin forced-expressing clones 4-1 and 4-2 was 14 
significantly higher (84% and 89%, respectively; p<0.05) than on control clone 1-5 (72%) 15 
(Fig. 3B). 16 
  17 
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DISCUSSION 1 
Previous studies showed that GdA inhibits NK cell activity, monocyte chemotaxis, T and B 2 
cell proliferation, and induces apoptosis in monocytes (Alok and Karande, 2009). In the 3 
present study, forced-expression of glycodelin in the HEC1-B cells did not significantly 4 
affect the cell cycle progression as confirmed by the cell proliferation assay, qPCR, and 5 
flow-cytometry analysis. 6 
Glycodelin has been found in breast cancer tissues and was detected in 50% of lymph 7 
node metastases, 38% of recurrent breast cancers, and 40% of breast cancers with distant 8 
metastases (Jeschke et al., 2005). Chemotherapy-treated ovarian cancer patients with 9 
higher glycodelin expression had longer survival times and less metastases than those with 10 
glycodelin-negative ovarian cancers at the same stages and differentiation grades 11 
(Koistinen et al., 2005). Moreover, GdA expression was significantly reduced in G2 12 
compared to G1 ovarian cancer tissue (Jeschke et al., 2005), but there was no change in 13 
cell cycle check point marker in the present study as confirmed by RT-PCR analysis. 14 
Similarly, ovarian cancer at surgical stage FIGO III-IV had a significantly lower GdA 15 
expression compared with FIGO I-II stage tumors (Tsviliana et al., 2010). From our 16 
findings, we suggest that glycodelin could be used as a biological marker for cancer 17 
progression. 18 
Forced-expression of glycodelin in the HEC1-B cell line inhibited endometrial 19 
epithelial cancer cell migration and invasion in vitro. The decrease in migration ability 20 
could be reversed when these cells were transfected with glycodelin RNAi. Forced-21 
expression of glycodelin in HEC1-B cells resulted in a reduction of carcinoma-associated 22 
gene expression, including MUC1 expression (Koistinen et al., 2005). MUC1 is an anti-23 
adhesive molecule that is overexpressed in many cancer cells and induces invasive growth 24 
and metastasis (Koistinen et al., 2005). A low level of MUC1 is associated with the 25 
reversal of malignancy (Coronado et al., 2001; Sivridis et al., 2002). 26 
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Other than cancer, migratory and invasive properties of endometrial epithelial cells 1 
were suggested to be responsible for endometriosis and adenomyosis (Chen et al., 2010; 2 
Dentillo et al., 2010; dos Santos Hidalgo et al., 2011). The main clinical features of 3 
endometriosis are pelvic pain and infertility (Giudice and Kao, 2004). Glycodelin is down-4 
regulated in eutopic endometrium tissue of endometriosis patients (Meola et al., 2009; Kao 5 
et al., 2003). These studies showed strong correlation between glycodelin and 6 
endometirosis. Together with role of glycodelin in other gynaecological diseases, 7 
glycodelin is responsible for number of pathways which affects steroid receptivity, growth 8 
and invasive potential in endometriotic tissues (Koistinen et al., 2005; Gaetje et al., 1995). 9 
In the current study, increase in glycodelin expression could reduce migratory and invasive 10 
property of endometrial epithelial cells, which might cause a reduction in endometriosis. 11 
Therefore, increase in glycodelin expression might contribute to advantage for successful 12 
implantation and pregnancy in an indirect way by minimizing the effect of endometriosis 13 
and up-regulation of receptive marker (Uchida et al., 2007).  14 
Blastocyst apposition and adhesion to the receptive endometrium are necessary steps 15 
to establish a successful implantation and pregnancy. In this study, forced-expression of 16 
glycodelin in HEC1-B was found to up-regulate the attachment rate of spheroid (blastocyst 17 
surrogate) onto the endometrial cells. Glycodelin was up-regulated in the endometrium 18 
during the receptive phase of the cycle (Liu et al., 2008). In humans, endometrial 19 
receptivity is highest at the mid-secretory phase of the menstrual cycle, in which 20 
glycodelin is highly expressed at the apical membranous protrusions called pinopodes 21 
(Stavreus-Evers et al., 2006). Pinopodes express adhesion surface molecules that are 22 
involved in embryo attachment (Lessey et al., 2000). At the adhesion phase of 23 
implantation, the embryo induces a paracrine cleavage of anti-adhesive molecule MUC1 in 24 
the endometrial epithelial cells (Meseguer et al., 2001). Other adhesive molecules such as 25 
integrins, heparin-binding epidermal growth factor-like growth factor, and leukemia 26 
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inhibitory factor are co-expressed on the pinopode during mid-secretory phase of 1 
menstrual cycle (Lessey et al., 2000; Aghajanova et al., 2003; Stavreus-Evers et al., 2002), 2 
and these promote attachment of embryo onto the receptive endometrium. Other molecules 3 
are found to suppress spheroid attachment onto endometrial cells in vitro, such as 4 
olfactomedin-1 that is down-regulated in the receptive endometrium (Kodithuwakku et al., 5 
2011). 6 
In conclusion, forced-expression of glycodelin in HEC1-B cells suppresses 7 
endometrial adenocarcinoma cell migration and invasion, but not cell cycle progression in 8 
vitro. Moreover, cells with forced-expression of glycodelin have higher rates of spheroid 9 
attachment than the controls, suggesting that an increased expression of glycodelin might 10 
favor embryo attachment in vivo. The use of glycodelin as a cancer marker and therapeutic 11 
target for gynecological cancer warrants further investigation. Moreover, forced-expression 12 
of glycodelin in human endometrium for fertility treatment should be explored.  13 
 14 
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FIGURE LEGENDS 1 
Figure 1 Effects of glycodelin forced-expression in HEC1-B cells on cell cycle 2 
progression. (A) Quantitative analysis of glycodelin mRNA expression in the HEC1-B 3 
cells transfected with empty vector control (Clone 1-5) and glycodelin expressing plasmid 4 
(Clones 4-1 and 4-2). Representative Western blotting of the transfected clones probed 5 
with anti-glycodelin and β-actin antibodies are shown on the right. (B) Flow cytometry 6 
analysis of the DNA content in the transfected clones (1-5, 4-1 and 4-2) at G0/G1, S and 7 
G2/M phase. The DNA content for cells in G2/M phase is higher than in S phase and 8 
G0/G1 phase (Right). All the experiments were performed in triplicates and repeated at 9 
least 3 times. 10 
 11 
Figure 2 Forced-expression of glycodelin in HEC1-B suppresses cell migration and 12 
invasion. (A) Forced-expression of glycodelin in clones 4-1 and 4-2 suppresses cell 13 
migration at 48 h compared to the control clone 1-5. (B) Forced-expression of glycodelin 14 
suppresses cell invasion at 24 h in clones 4-1 and 4-2 but not in control clone 1-5 (Scale 15 
bar, 100m). (C) Transfection of glycodelin RNAi (Gd) suppressed glycodelin expression 16 
(left panel) and restored the cell migration rate (right panel) in clone 4-1. No effect was 17 
observed when the cells were transfected with transfection reagent (-) or non-target (NT) 18 
RNAi control. There was no change in cell migration rate in control clone 1-5 when 19 
transfected with glycodelin or non-target RNAi. a-b denotes significant difference from 20 
each other at p<0.05.  All the experiments were performed in triplicates and repeated at 21 
least 3 times. 22 
 23 
Figure 3 Forced-expression of glycodelin in the transfected HEC1-B cells stimulates 24 
spheroid attachment. (A) Spheroids (60-200 m) were prepared from JAr cells for the co-25 
culture study (Scale bar, 100 μm). (B) The spheroid attachment rates of clones 4-1 and 4-2 26 
  18
were significantly higher (p<0.05, a-b) than in the control clone 1-5. The results were 1 
obtained from three or more pooled experiments and the total number of spheroids used 2 
per group was more than 200. 3 
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